<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00989690</url>
  </required_header>
  <id_info>
    <org_study_id>SRSI-HSRL-02-2007</org_study_id>
    <secondary_id>CDR0000652115</secondary_id>
    <secondary_id>2007-006299-13</secondary_id>
    <secondary_id>EU-20975</secondary_id>
    <nct_id>NCT00989690</nct_id>
  </id_info>
  <brief_title>Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>Randomized Proteomic Stratified Phase III Study of Second-Line Erlotinib Versus Chemotherapy in Patients With Inoperable Non Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Scientifico H. San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying the proteins expressed in samples of blood and tissue from patients with&#xD;
      cancer may help doctors identify biomarkers related to cancer. It may also help doctors&#xD;
      predict how patients will respond to treatment.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying blood and tissue samples in predicting&#xD;
      response to second-line therapy using erlotinib hydrochloride or chemotherapy in patients&#xD;
      with advanced non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To evaluate the predictive value of proteomic profiling on the effect of second-line&#xD;
           therapy with erlotinib hydrochloride vs standard chemotherapy (pemetrexed disodium or&#xD;
           docetaxel) in patients with advanced non-small cell lung cancer.&#xD;
&#xD;
        -  To assess the role of other known tissue-based predictive markers (e.g., EGFR-gene copy&#xD;
           number, EGFR-protein expression, pAkt, pMAPK, EGFR mutations, EMT markers, and k-Ras&#xD;
           mutation).&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to smoking status,&#xD;
      performance status, proteomic profile, and participating center. Patients are randomized to 1&#xD;
      of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive standard chemotherapy with pemetrexed disodium, docetaxel, or&#xD;
           another standard drug.&#xD;
&#xD;
        -  Arm II: Patients receive standard non-chemotherapy treatment with erlotinib&#xD;
           hydrochloride.&#xD;
&#xD;
      Serum is collected after failure of first-line therapy for proteomic analysis by&#xD;
      matrix-associated laser desorption/ionization-time of flight. Tissue and blood samples are&#xD;
      collected periodically for analysis including EGFR based on IHC and FISH, EGFR and k-Ras&#xD;
      mutations, pAkt, pMAPK by IHC, and EMT markers based on IHC and breath condensate protein&#xD;
      profile.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 2 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate according to RECIST criteria</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">275</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed disodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>fluorescence in situ hybridization</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>proteomic profiling</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>matrix-assisted laser desorption/ionization time of flight mass spectrometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>breath test</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of non-small cell lung cancer&#xD;
             (NSCLC)&#xD;
&#xD;
               -  Advanced NSCLC (stage IIIB or IV)&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Underwent previous treatment with 1 non-tyrosine kinase inhibitor as first-line&#xD;
             therapy for advanced NSCLC&#xD;
&#xD;
          -  No clinical evidence of uncontrolled brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Caucasian&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN) (≤ 2.5 times ULN in patients with&#xD;
             known liver metastases)&#xD;
&#xD;
          -  ALT or AST ≤ 3 times ULN (≤ 5 times ULN in patients with known liver metastases)&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Able to comply with planned study procedures&#xD;
&#xD;
          -  No multiple severe diseases that can compromise safety (cardiac and renal failure,&#xD;
             peripheral neuropathy)&#xD;
&#xD;
          -  No other malignancy (except for basal cell skin carcinoma) or pre-neoplastic condition&#xD;
             requiring chemotherapeutic treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior surgery or radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vanesa Gregor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Scientifico H. San Raffaele</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Scientifico H. San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanesa Gregor, MD</last_name>
      <phone>39-02-2643-7623</phone>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>October 2, 2009</study_first_submitted>
  <study_first_submitted_qc>October 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2009</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

